For which patients with breast cancer is Tyverb indicated in combination with an aromatase inhibitor?

Tyverb with an aromatase inhibitor is indicated for adult postmenopausal women with HER2-overexpressing, hormone receptor-positive metastatic breast cancer not currently intended for chemotherapy; registration-study patients had no prior trastuzumab or aromatase inhibitor, and efficacy relative to trastuzumab plus an aromatase inhibitor is unknown.